Swartling, Fredrik J.

Medulloblastomics revisited: biological and clinical insights from thousands of patients

Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer

Glioma Diagnosis and TreatmentNeuroblastoma Research and Treatments

Cited by 271

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 210

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment

Cited by 119